Format

Send to

Choose Destination
Clin Infect Dis. 1992 May;14(5):1089-99.

beta-Lactamases of gram-negative bacteria: new challenges for new drugs.

Author information

1
Department of Medical Microbiology, Creighton University School of Medicine, Omaha, Nebraska 68178.

Abstract

The major emphasis in new drug design within the beta-lactam family has been on compounds less susceptible to hydrolysis by beta-lactamases and on combinations containing an enzyme-labile drug plus a beta-lactamase inhibitor. The introduction of such new compounds into clinical use has been followed by the discovery of novel mechanisms of resistance among gram-negative bacteria. These include the appearance of new enzymes, many of which are derivatives of older beta-lactamases. In addition, genes for certain broad-spectrum enzymes previously restricted to chromosomal sites have moved onto plasmids. There is now a greater appreciation of how alterations in enzyme expression--either alone or in concert with changes in drug permeation--can also lead to resistance. Clearly, recent events in the development of new beta-lactam agents have led to a new phase in the understanding of beta-lactam resistance.

PMID:
1600011
DOI:
10.1093/clinids/14.5.1089
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center